Skip to main content

Advertisement

Table 5 Summary or studies on the use of salvage stereotactic radiosurgery for recurrent glioblastoma

From: Stereotactic radiosurgery for glioblastoma: retrospective analysis

Institution (year) #rGB/# total Median dose [range] (Gy) Prescription MS (M) Late toxicity
Brigham & Women's Hosp. (1995) [22] 86/86 13 [620] 50–90% IDL
Median 80%
10 19 pathologic necrosis
1 CN palsy
U. Pittsburgh (1997) [23] 19/107 NR NR 30 1 symptomatic necrosis
12 pathologic necrosis (of 60 GB patients)
U. Minnesota (1999) [24] 27/46 17 [940] 30–90% IDL
Median 50%
7 8 pathologic necrosis
6 clinical necrosis
U. Wisconsin (1999) [25] NR/30 NR 50–80% IDL 7 NR
Cleveland Clinic (2000) [26] 23/23 15 [1220] 50–80% IDL 10 1 pathologic necrosis
2 increased seizures
UCSF (2002) [27] 14/26 [~10–22] 50% IDL 10 Not assessable
UCSF (2002) [27] 39/54 [~12–18]
+ marimastat
25–30% IDL 9 Not assessable
U. Heidelberg (2005) [28] 32/32 15 [1020] 80% IDL covers tumor 10 None
MDACC (2005) [29] 40/40 NR NR 11 8 pathologic necrosis
Henry Ford (2007) [30] 26/26 NR 18 Gy at margin 9 NR
Current series 18/33 15 [920] 80% IDL covers tumor 7 See text
  1. Abbreviations: rGB = recurrent glioblastoma, GB = glioblastoma, SRS = stereotactic radiosurgery; IDL = isodose line. NR = not reported.